Jump to content
PathLabTalk

DTT-Treatment of Screening Cells (Daratumumab/Darzalex)


septima
 Share

Recommended Posts

1 hour ago, amym1586 said:

We are a little late to the ball game.  But there's some confusion in the lab about what RBC's are being DTT Treated.    Reagent cells, patient cells, donor cells?   

Can anyone shine some light for us. 

Reagent cells.  The cells are used to try to see if there are any alloantibodies underlying the monoclonal anti-CD antibodies.

Link to comment
Share on other sites

1 hour ago, amym1586 said:

We are a little late to the ball game.  But there's some confusion in the lab about what RBC's are being DTT Treated.    Reagent cells, patient cells, donor cells?   

Can anyone shine some light for us. 

Most typically Screening Cells will be treated. If that screen is negative, then no further action is required (except perhaps antigen-typing the patient). If the DTT-treated screen is positive, it may be necessary to DTT-treat a reagent red cell panel (or selected cells).

Link to comment
Share on other sites

  • 5 months later...
  • 4 months later...
On 10/18/2017 at 3:12 PM, BloodbankZ said:

Has anybody tried DTT treating reagent red blood cells in MTS gel method? If so are you concentrating your cells before treating or have adjusted your ratio of DTT to the .8% suspension? TIA.

We are looking to bring DTT treatment in house as well.  Still working out the details and hoping to have the same question answered - does anyone test the treated cells in MTS-Gel?  It seemed to work well for me when I experimented with it.  

Link to comment
Share on other sites

When I tried to run it in gel I never could get nice clean reactions. Their would always be particulate at the top of the wells. I have seen several tube procedures that are just using so many drops of 4% cell suspensions instead of concentrating their cells and then getting an exact 4:1 ratio with DTT. I have since went to doing it in tube. What kind of steps are you performing?

Link to comment
Share on other sites

I performed this study of long term stability (14 days) of panel cells treated in bulk as my SBB project. I also used regular blood bank saline vs the 8.0 from the technical manual. I was able to publish my study and findings in the Immunohematology journal. I would be happy to share if you leave your email address. Happy to help those interested. 

Link to comment
Share on other sites

If patient on DARA how soon they can develop pan-reactive antibody? We had our first patient who is on DARA had negative  antibody screen before treatment after 36 hours of treatment antibody screen is positive in all 3 cell line. Patient's antibody panel  shows some pan-reactive reaction with 8 out of 11 cells .But auto is negative . Is it due to DARA or patient is developing some allo antibody?

 

Edited by gagpinks
Link to comment
Share on other sites

On ‎3‎/‎10‎/‎2018 at 4:30 AM, gagpinks said:

If patient on DARA how soon they can develop pan-reactive antibody? We had our first patient who is on DARA had negative  antibody screen before treatment after 36 hours of treatment antibody screen is positive in all 3 cell line. Patient's antibody panel  shows some pan-reactive reaction with 8 out of 11 cells .But auto is negative . Is it due to DARA or patient is developing some allo antibody?

 

I would say it is due to the DARA. DTT treated cells will eliminate the DARA reactivity and let you be able to rule out everything besides mainly Kell system which DTT denatures. We perform a baseline type and screen and DNA HEA typings on patients before they start. If DTT screen is negative we give K negative cells if patient is antigen negative.

Link to comment
Share on other sites

Further follow up.  We did purchase the HemoBioScience premade DTT - very nice and really not too expensive for a small hospital - saves all the worry over the manufacture of an in-house DTT reagent. 

Works well to use 8-10 drops of your 3-4% RBC reagent cells to make one drop of "Packed" RBCs to treat with 4 drops of DTT.  Once they are treated and washed, you remake to a 3% solution and get 8-10 drops of treated cells to work with.  As hard as the DTT treatment is on the reagent cells - I don't think they are going to last very long for a small hospital - maybe a day or two for a reference lab??  (didn't see the results of that validation study.)

We treat the reagent cells (I, II, III) and the first RBCs requested for crossmatch every 72 + hours (new specimen), but if the antibody screen was negative - we just continue with K neg , immed spin, type specific RBCs for the 72 hours (same specimen) for any add-on units. 

If the antibody screen is positive - a reference lab is going to get the workup.  We only have one liquid panel, so I can't see us being able to work up an underlying allo antibody in-house.

Dr still is not happy that it takes someone 3-4 hours to work one of these pts up - go figure.  It is amazing that even an Oncology specialist thinks that just because we did an antibody screen 3 months ago - we should be fine with giving them "some of that least incompatible stuff"! 

oh well - will attach my SOP for DTT for anyone it might help.  We can survive the simple pts with this procedure here - don't look forward to the 1st pt that forms an allo-antibody on top of the DARA.

DTT SOP.pdf

Link to comment
Share on other sites

20 minutes ago, cswickard said:

Dr still is not happy that it takes someone 3-4 hours to work one of these pts up - go figure.  It is amazing that even an Oncology specialist thinks that just because we did an antibody screen 3 months ago - we should be fine with giving them "some of that least incompatible stuff"! 

Don't you just love 'em?  Doctors know everything!

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share

  • Similar Content

    • By kris6026
      For those of you treating cells with DTT for patients taking daratumumab/darzalex: Have you come across a positive autocontrol, with treated and untreated cells? 
      Currently, patient on DARA: initial screen-panagglutinin, auto-positive.
      Testing with treated cells: screen-negative, auto-positive.
      QC-valid (testing Kpos and Epos cell) antigen typing for K-neg, E-pos
      I have been unable to find any research with this information.  We are currently in the process of validating DTT treatment. 
      Any advice would be welcomed.
      Thank you
    • By KarenJ
      We are getting full genotype on our dara patients before they start on the drug.   Currently we have one patient that requires transfusion and are giving matched blood.  Our question is how often should we send a sample to our reference lab for testing?  There doesn't seem to be a whole lot of agreement on what to do.  Every 72 hours is unrealistic.  Any guidance would be appreciated.   Thanks,  Karen
    • By PMcPeek
      Looking for others in smaller hospital settings encountering DARA patients in blood bank; we plan to send affected antibody screens and crossmatches to our blood center's reference lab for workup and have them send us crossmatched units.  Currently we do not plan to add DTT to our in-house testing, just rely on the reference lab due to the size of our blood bank.   Curious if this is working for others.  In event of emergency, do you release uncrossmatched?  try to do IS XM?   Would like to know what others are doing and how it's working.  Thanks in advance!
    • By jeloweryii
      Hemo bioscience, an established and growing biotechnology company headquartered in Research Triangle Park (RTP), North Carolina, develops and manufactures immunohematology reagents and related products for the world wide transfusion diagnostics market. Our customers include industry partners, reference laboratories, buying groups, hospital blood banks, and donor centers. Hemo bioscience's in-house research, development and manufacturing activities are led by blood bank trained scientists who are committed to improving the science of transfusion technology.
      When life depends on reliable results, you can rely on Hemo bioscience - "The science in blood banking"
  • Advertisement

×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.